Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, inhibit glucose reuptake in the kidneys to lower blood sugar without causing hypoglycemia (168). Here, SLC5A2 is linked to Hypoglycemia.